In our study, the initial decline in eGFR after initiating SGLT2 inhibitor therapy was smaller in patients with FD compared to those with other forms of CKD, indicating that hemodynamic changes, such as reduced intraglomerular pressure, may play a limited role in FD. This evidence concerns the gene SLC5A2 and chronic kidney disease.